Journal of Virology & Antiviral ResearchISSN: 2324-8955

Research Article, J Virol Antivir Res Vol: 2 Issue: 3

Enhanced Fitness of Non-Pathogenic SHIV-NM-3rN Over Acute Pathogenic 89.6P in a Dual Infection/Compitition Assay on HSC-F Monkey Derived Cell Line

Kwofie Theophilus Benjamin1* and Miura Tomoyuki2
1Department of Clinical Microbiology, School of Medical Sciences, College Health Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
2Laboratory of Primate Model, Experimental Research Center for Infectious Diseases, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan
Corresponding author : Kwofie TB, Ph.D
Department of Clinical Microbiology, School of Medical Sciences, College Health Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
Tel: +233 24 4097732; Fax: +233 3220 60302
E-mail: [email protected]
Received: August 19, 2013 Accepted: September 11, 2013 Published: September 13, 2013
Citation: Kwofie TB, Miura T (2013) Enhanced Fitness of Non-Pathogenic SHIV-NM-3rN Over Acute Pathogenic 89.6P in a Dual Infection/Compitition Assay on HSC-F Monkey Derived Cell Line. J Virol Antivir Res 2:3. doi:10.4172/2324-8955.1000113

Abstract

Enhanced Fitness of Non-Pathogenic SHIV-NM-3rN Over Acute Pathogenic 89.6P in a Dual Infection/Compitition Assay on HSC-F Monkey Derived Cell Line

In a study to use a non-pathogenic Simian/Human Immunodeficiency Virus (SHIV) to overcome pathogenic SHIV in a dual infection/competition assay, two SHIVs, pathogenic 89.6P and non-pathogenic NM-3rN, whose replicative fitness were adjusted to be of equal strength, were mixed together and allowed to compete during many transfers in a monkey-derived cell line HSC-F. This is to identify the conditions under which a nonpathogenic SHIV could out-compete a pathogenic SHIV in order to understand the principles underlying evolution of adaptation and selection and to see if the underlying principle could serve as a guide in the design of a therapeutic Human Immunodeficiency Virus (HIV) vaccine.

Keywords:

Track Your Manuscript

Share This Page

Media Partners